CRISPR Therapeutics AG (CRSP) Free Cash Flow (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Free Cash Flow of -$109.4 million for Q1 2026, down 17.55% sequentially from -$93.1 million in Q4 2025, and down 102.02% YoY from $5.4 billion in Q1 2025.
CRISPR Therapeutics AG (CRSP) Free Cash Flow (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Free Cash Flow for 12 years, with the latest figure at -$109.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 102.02% year-over-year to -$109.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$401.2 million (down 31.06% YoY) and the FY2025 annual result came in at -$345.9 million, down 142.03% from the prior year.
- Free Cash Flow slipped to -$109.4 million in Q1 2026 per CRSP's latest filing, from -$93.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $109.0 million in Q1 2024 and troughed at -$161.0 million in Q2 2022.
- A 5-year average of -$79.8 million and a median of -$96.0 million in 2023 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 1799.49% in 2024, down 170.67% in 2024.
- Over 5 years, Free Cash Flow stood at -$110.5 million in 2022, then grew by 13.11% to -$96.0 million in 2023, then soared by 49.46% to -$48.5 million in 2024, then sank by 91.75% to -$93.1 million in 2025, then fell by 17.55% to -$109.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$109.4 million, -$93.1 million, and -$84.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -84.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.15 Mn |
| Jun 30, 2026 | -84.15 Mn |
| Mar 31, 2026 | -109.40 Mn |
| Mar 31, 2026 | -109.40 Mn |
| Dec 31, 2025 | -93.07 Mn |
| Dec 31, 2025 | -93.07 Mn |
| Sep 30, 2025 | -84.71 Mn |
| Sep 30, 2025 | -84.71 Mn |
| Jun 30, 2025 | -114.00 Mn |
| Jun 30, 2025 | -114.00 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -48.54 Mn |
| Dec 31, 2024 | -48.54 Mn |
| Sep 30, 2024 | -107.13 Mn |
| Sep 30, 2024 | -107.13 Mn |
| Jun 30, 2024 | -96.29 Mn |
| Jun 30, 2024 | -96.29 Mn |
| Mar 31, 2024 | 109.03 Mn |
| Mar 31, 2024 | 109.03 Mn |